Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Abbott launches Freenome's colorectal cancer screening test

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

Abbott has launched the SimpleScreen colorectal cancer screening test developed by Freenome in the U.S., complementing the Cologuard Plus stool-based test acquired through Exact Sciences.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 30 Sep 2026 and 2 Oct 2026.

◆ ◆ The Wire takeaway

You now face direct competition from Abbott combining genetic and stool-based colorectal cancer tests in the US. This signals a moment to highlight distinct accuracy or cost advantages in your screening approach.

◆ Coverage

4 sources · first reported 30 Sep 2026 · latest 2 Oct 2026

◆ Related on Wire

◆ Topics

Medtechcancer-screeningcolorectal-cancerdiagnosticsmedtechus-market